As products targeting everyday health concerns such as better sleep and weight management spread rapidly, the risks of supplements and injections used outside medical supervision have also grown. In particular, products promoted through overseas direct purchases and social media advertising, such as gummies containing ashwagandha root extract, as well as obesity treatments used outside prescription controls, have shown that they can lead to serious adverse reactions such as acute pancreatitis. This trend can be seen as the result of a combination of the perception that natural substances or health functional foods are relatively mild and consumer demand for quick results. The key issue is that risk can vary greatly depending not just on whether a product is effective, but also on the duration of use, dosage, concomitant medications, and distribution channels; accordingly, prior verification and consultation have now become more important than freedom of choice alone.

In the beauty market, a strong trend has emerged in which sales performance in distribution channels, rather than laboratories or advertising, serves as the first proof of a product’s credibility. As Daiso has expanded its cosmetics assortment to more than 2,200 items, it has become a starting point where overseas buyers directly discover products and manufacturers, while Olive Young is increasingly functioning as an on-site showroom for visitors to Korea as foreign offline purchases grow rapidly. This shift has occurred because brands are moving beyond simple shelf-placement competition and are beginning to use distribution networks themselves as tools for export validation and data collection. As companies also expand models that combine content and sales, such as AI- and XR-based wellness inner beauty tech platforms, distribution is evolving beyond a sales outlet into core infrastructure that shapes product planning and overseas expansion.

Auto insurance has shifted toward more stringent management of treatment for minor injuries. In particular, patients with minor injuries classified as injury grades 12 to 14 must now undergo external review if they seek treatment beyond eight weeks, putting the brakes on the customary practice of prolonged treatment. This change is less about simply reducing some medical services and more about controlling accumulated insurance payouts. For minor injury patients, it effectively blocks the broadly recognized payment of future treatment costs during settlements, with the aim of realigning actual medical necessity and the scope of compensation.

The Ministry of Food and Drug Safety (MFDS) has set a goal of introducing abortion medication into the formal healthcare system by the first quarter of next year. In this process, it has become more apparent that the agency is leaning away from requiring additional trials involving Korean participants, apparently seeking to accelerate domestic approval procedures based on the extensive body of usage experience already accumulated across diverse races and countries. This approach aligns with a recent regulatory trend of placing less emphasis on additional local clinical trials when global usage data are considered sufficient. However, because this is a socially sensitive drug, a faster approval decision does not automatically resolve safety concerns, making the design of post-marketing management and distribution controls all the more important.

The starting point of sleep management is rapidly shifting from hospital sleep labs to everyday devices. Apple used more detailed heart rate and sleep data on the Apple Watch 12 and Ultra 4 to generate a daily condition score, while Samsung linked sleep, activity, and vascular strain on the Galaxy Watch Ultra 2 and Watch 9 to heart health assessments. This change has emerged because sleep is no longer seen merely as a matter of fatigue, but as a key input for reading cardiovascular risk and recovery status. As a result, the scope of personal self-management has expanded, and health data shared among family members is creating new boundaries between care and surveillance.

Quality control for herbal medicinal materials is shifting from reliance on expert experience to data-driven and molecular-level verification. To reduce the risk of source-species mixing and misidentification, the Ministry of Food and Drug Safety has established standard procedures for developing genetic analysis methods, systematizing DNA-based testing criteria, while also expanding an AI inspection system that supports visual identification. This change stems from the structural limitation that herbal materials become difficult to distinguish by sight alone once they are dried and cut. As inspection standards become more quantifiable, disputes in distribution can be reduced, and manufacturers are being made to bear clearer responsibility for raw material selection and incoming goods management.

Offline beauty retail is shifting away from simple display competition toward expert consultation and function-focused curation. The emergence of stores that incorporate pharmacies, such as [Musinsa Beauty Hongdae], and derma-specialized select shops like [Cooode] reflects a structural response by distributors to consumers who are increasingly scrutinizing ingredients and product purposes. Behind this shift is a consumption pattern in which the boundary between beauty and health management has narrowed. In particular, as the [share of pharmacy spending] grows alongside foreign demand for medical and beauty services, pharmacies are being reinterpreted not just as places to buy medicine, but as points of connection linking high-functionality cosmetics and inner beauty products.

Starting in October, the review of herbal decoctions and pharmacopuncture under automobile insurance will be expanded to cover a broader group of patients with minor injuries, and patients with mild injuries who seek treatment beyond eight weeks will be subject to separate review. Until now, there had been a mismatch between the legal scope of minor-injury patients and the scope actually applied in reviews, meaning that even injuries of the same severity were managed differently depending on the diagnosis name. This adjustment is largely aimed at narrowing that gap. Behind the change is the concern that long-term treatment and the practice of claiming future treatment costs have contributed to higher loss ratios in automobile insurance and increased premium burdens. As a result, patients and medical institutions will need to explain the necessity of treatment in a more structured way, and the insurance system will shift its focus from simple payment to appropriateness management.

Korea’s domestic mRNA technology is moving beyond the phase of hurriedly catching up during infectious disease outbreaks and toward building its own platforms while internalizing manufacturing quality. The backdrop to GC Pharma’s entry of GC4006A into domestic Phase 2 trials, the Chonnam National University consortium’s launch of a long-term immunity-inducing vaccine platform, and the AI-based manufacturing initiative centered on Gwangju and Hwasun is a policy goal of reducing the burden of repeated vaccinations while also lowering dependence on overseas technology. The significance of this trend is that vaccines are being redefined not by the success of a single product, but as industrial capability spanning design, production, quality control, and follow-on expansion. In particular, efforts to link AI to process variability management show that the industry’s standards are shifting toward reproducibility and stability rather than speed of development.